Zepbound bests Wegovy for weight loss in new trial
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.
Source: Medical Xpress
Thank you for choosing TeleSlim Clinic in Illinois!
We accept cash-pay patients in Illinois — no insurance hassles.
Choose an option below to get started.
Close